Lunsayil LTE: An extension trial assessing long-term spesolimab treatment in patients with Hidradenitis Suppurativa (HS)

Status

Completed

Phases

Phase 2Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-508377-82-00

Acronym

1368-0130

Enrollment

Registered

2024-06-03

Start date

2024-06-27

Completion date

2025-03-31

Last updated

2025-02-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hidradenitis Suppurativa (HS)

Brief summary

Occurrence of treatment emergent adverse events (TEAE)

Interventions

DRUGSpesolimab

DRUGPlacebo matching to Spesolimab

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Occurrence of treatment emergent adverse events (TEAE)	—

Countries

Austria, Belgium, Bulgaria, Czechia, Denmark, Finland, France, Germany, Greece, Italy, Lithuania, Poland, Slovakia, Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026